CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Presented at SABCS 2021, the EMERALD Study of elacastrant and the PHOEBE Trial of pyrotinib showed a better than doubling of 12-month PFS with the first agent, and an improvement in both OS and PFT with the second agent. And the results of the DESTINY-Breast03 study have been called “practice changing.”
Peer-influenced content. Sources you trust. No registration required. This is HCN.
